Biopharmaceutics and Bioequivalence

This research group is pledged to investigate the relationship between the physicochemical properties of drugs, their dosage forms, and their therapeutic performance. The group focuses on the study of drug absorption, distribution, metabolism, and excretion (ADME) to optimize formulations and enhance bioavailability. It also conducts bioequivalence studies to compare the pharmacokinetic profiles of generic formulations with their branded counterparts, ensuring therapeutic equivalence and interchangeability. Utilizing both in vitro dissolution testing and in vivo pharmacokinetic modeling, the team contributes to quality assurance and regulatory compliance in pharmaceutical product development. Through these efforts, the group actively supports the national objective of promoting high-quality, affordable generic medicines for the communities.

INTEREST(S)

-

MODERATOR

VISION

The vision of the Biopharmaceutics and Bioequivalence Research Group is to establish itself as a globally competitive center for excellence in drug formulation, pharmacokinetic, and bioequivalence research. The group aspires to contribute to the growth of Bangladesh’s pharmaceutical industry by fostering innovation, ensuring product reliability, and promoting scientific integrity in drug development. Through cutting-edge research, collaboration, and regulatory alignment, the group envisions strengthening the country’s capacity to provide safe, effective, and accessible medicines for all.

MISSION

The mission of the Biopharmaceutics and Bioequivalence Research Group is to advance scientific understanding of the relationships among drug properties, formulation design, and therapeutic outcomes. By conducting comprehensive studies on absorption, distribution, metabolism, and excretion (ADME), the group seeks to optimize drug formulations for enhanced bioavailability and clinical efficacy. Through rigorous bioequivalence and pharmacokinetic studies, the team is dedicated to ensuring the safety, quality, and therapeutic equivalence of pharmaceutical products—supporting the development of affordable, high-quality generic medicines that comply with national and international regulatory standards.

MEMBER(S)